CTXR Quote, Financials, Valuation and Earnings

Citius Oncology, Inc. has a net margin of -- compared to Citius Pharmaceuticals, Inc.'s net margin of --. Citius Pharmaceuticals, Inc.'s return on equity of -56.5% beat Citius Oncology, Inc.'s return on equity of -64.23%.

Citius Pharmaceuticals, Inc. has a consensus price target of $6.00, signalling upside risk potential of 613.61%. On the other hand Citius Oncology, Inc. has an analysts' consensus of $6.00 which suggests that it could grow by 430.97%. Given that Citius Pharmaceuticals, Inc. has higher upside potential than Citius Oncology, Inc., analysts believe Citius Pharmaceuticals, Inc. is more attractive than Citius Oncology, Inc..

Citius Pharmaceuticals, Inc. has a beta of 1.509, which suggesting that the stock is 50.851% more volatile than S&P 500. In comparison Citius Oncology, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Citius Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Citius Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Citius Oncology, Inc. pays out -- of its earnings as a dividend.

Citius Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Citius Oncology, Inc. quarterly revenues of --. Citius Pharmaceuticals, Inc.'s net income of -$8.7M is lower than Citius Oncology, Inc.'s net income of -$5M. Notably, Citius Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Citius Oncology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Pharmaceuticals, Inc. is -- versus -- for Citius Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Dermata Therapeutics, Inc. has a net margin of -- compared to Citius Pharmaceuticals, Inc.'s net margin of --. Citius Pharmaceuticals, Inc.'s return on equity of -56.5% beat Dermata Therapeutics, Inc.'s return on equity of -190.86%.

Citius Pharmaceuticals, Inc. has a consensus price target of $6.00, signalling upside risk potential of 613.61%. On the other hand Dermata Therapeutics, Inc. has an analysts' consensus of $10.00 which suggests that it could grow by 437.63%. Given that Citius Pharmaceuticals, Inc. has higher upside potential than Dermata Therapeutics, Inc., analysts believe Citius Pharmaceuticals, Inc. is more attractive than Dermata Therapeutics, Inc..

Citius Pharmaceuticals, Inc. has a beta of 1.509, which suggesting that the stock is 50.851% more volatile than S&P 500. In comparison Dermata Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Citius Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dermata Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Dermata Therapeutics, Inc. pays out -- of its earnings as a dividend.

Citius Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Dermata Therapeutics, Inc. quarterly revenues of --. Citius Pharmaceuticals, Inc.'s net income of -$8.7M is lower than Dermata Therapeutics, Inc.'s net income of -$1.7M. Notably, Citius Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Dermata Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Pharmaceuticals, Inc. is -- versus -- for Dermata Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Dynavax Technologies Corp. has a net margin of -- compared to Citius Pharmaceuticals, Inc.'s net margin of 28.38%. Citius Pharmaceuticals, Inc.'s return on equity of -56.5% beat Dynavax Technologies Corp.'s return on equity of -7.65%.

Citius Pharmaceuticals, Inc. has a consensus price target of $6.00, signalling upside risk potential of 613.61%. On the other hand Dynavax Technologies Corp. has an analysts' consensus of $20.50 which suggests that it could grow by 33.29%. Given that Citius Pharmaceuticals, Inc. has higher upside potential than Dynavax Technologies Corp., analysts believe Citius Pharmaceuticals, Inc. is more attractive than Dynavax Technologies Corp..

Citius Pharmaceuticals, Inc. has a beta of 1.509, which suggesting that the stock is 50.851% more volatile than S&P 500. In comparison Dynavax Technologies Corp. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.435%.

Citius Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dynavax Technologies Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Dynavax Technologies Corp. pays out -- of its earnings as a dividend.

Citius Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Dynavax Technologies Corp. quarterly revenues of $94.9M. Citius Pharmaceuticals, Inc.'s net income of -$8.7M is lower than Dynavax Technologies Corp.'s net income of $26.9M. Notably, Citius Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Dynavax Technologies Corp.'s PE ratio is 54.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Pharmaceuticals, Inc. is -- versus 6.43x for Dynavax Technologies Corp.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Citius Pharmaceuticals, Inc.'s net margin of -255.85%. Citius Pharmaceuticals, Inc.'s return on equity of -56.5% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Citius Pharmaceuticals, Inc. has a consensus price target of $6.00, signalling upside risk potential of 613.61%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.47%. Given that Citius Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Citius Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Citius Pharmaceuticals, Inc. has a beta of 1.509, which suggesting that the stock is 50.851% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Citius Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Citius Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Citius Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Citius Pharmaceuticals, Inc.'s net income of -$8.7M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Citius Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Pharmaceuticals, Inc. is -- versus 9.42x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.